Organoidsciences Ltd. (KOSDAQ:476040)

Market Cap	193.61B
Revenue (ttm)	2.55B +37.4%
Net Income	-13.83B
EPS	-2,392.44
Shares Out	6.59M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	188,531
Average Volume	157,222
Open	30,300
Previous Close	31,300
Day's Range	28,800 - 30,800
52-Week Range	23,000 - 52,000
Beta	n/a
RSI	34.59
Earnings Date	Mar 27, 2026

About Organoidsciences

Organoidsciences Ltd. develops regenerative therapies in South Korea. It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions. The company was founded in 2018 and is based in Seongnam-si, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 476040

Financial Performance

In 2024, Organoidsciences's revenue was 1.95 billion, an increase of 22.77% compared to the previous year's 1.59 billion. Losses were -11.25 billion, -70.93% less than in 2023.